We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 76.97 | 77.06 | 77.29 | 0 | 01:00:00 |
From May 2019 to May 2024
By Sabela Ojea
AstraZeneca PLC said Friday that the combination of its Imfinzi drug and tremelimumab with chemotherapy showed an overall survival benefit in its metastatic non-small cell lung cancer Phase 3 Poseidon trial.
The pharmaceutical company added that the use of Imfinzi with chemotherapy didn't achieve a trend in overall survival.
"We've seen encouraging uptake of novel combinations in this setting and believe this new approach will add a further option for patients with high unmet medical need," said Dave Fredrickson, executive vice president of Astrazeneca's oncology business unit.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 07, 2021 02:33 ET (06:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
